s28048
NM_001199261.1
NM_001199262.1
NM_001199263.1
NM_015984.3
NR_037607.1
XM_005245244.4
XM_005245246.4
XM_005245247.4
XM_005245248.4
XM_005245249.4
XM_006711366.3
XM_006711367.3
XM_006711368.3
XM_006711369.2
XM_006711370.3
XM_006711371.3
XM_011509604.1
XM_011509607.2
XM_011509608.2
XM_011509609.2
XM_017001429.1
XM_017001430.1
XM_017001431.1
XM_017001432.1
XM_017001433.1
XM_017001434.1
XM_017001435.1
XM_017001436.1
XM_017001437.1
XM_017001438.1
XM_017001439.1
XM_017001440.1
XM_017001441.1
XM_017001442.1
XM_017001443.1
XM_017001444.1
4%(+/-1% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00255374_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.